Clinical Trial

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Study acronym: ECLECTIC
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2023-12-22; most recent amendment 2026-04-16.
Status change: Not Yet Recruiting → Recruiting 2024-04-17
Trial Details
NCT Number NCT06195709
Lead Sponsor Institut Curie
Collaborators: Zionexa
Conditions Breast Carcinoma
Enrollment 300 participants
Start Date 2024-05-27
Primary Completion 2029-09-27 (estimated)
Study Completion 2030-09-27 (estimated)
Updated on ClinicalTrials.gov 2026-04-17